Evidence map›Paper›PMID 42151256›Full record

ArticleScientific reports2026

Synthesis and anti-antileishmanial profile of novel thiazolidine-4-one derivatives and molecular docking and molecular dynamics simulations studies.

Soheila Molaei, Jafar Abbasi Shiran, Arina Esmailzadeh, Soroush Rajabi, Mohammad Reza Rahimi, Yasamin Abedini Zal, Saghi Sepehri

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Soheila MolaeiZoonoses Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Jafar Abbasi ShiranPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Arina EsmailzadehDepartment of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Soroush RajabiStudents Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Mohammad Reza RahimiStudents Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Yasamin Abedini ZalStudents Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.
Saghi SepehriPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran. saghisepehridr@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a severely neglected intracellular protozoan disease caused by infection with parasites of the Leishmania genus, affecting over 98 countries globally. Presently, the infection threatens the health of more than 350 million people globally, resulting in an estimated 60,000 deaths yearly from both visceral and cutaneous forms of the parasite. In present research, a novel series of thiazolidine-4-one analogues (7a-g) was synthesized and evaluated against Leishmania major. In vitro assays demonstrated using Leishmania major promastigotes and amastigotes, while cytotoxicity was assessed on the J

Indexed as

Antiprotozoal AgentsLeishmania majorThiazolidinesAnimalsApoptosisCell LineMacrophagesMiceMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipAntiprotozoal AgentsThiazolidinesLeishmaniasisNeglected tropical diseasesThiazolidinone coreZoonotic importance

Identifiers

PMID42151256
PMCPMC13376208

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.